An overview of overactive bladder and its pharmacological management with a focus on anticholinergic drugs

P and T

Volumn 31, Issue 8, 2006, Pages 462-474

  DeMaagd, George ^a   Geibig, Jeffrey D ^b  

^a FERRIS STATE UNIVERSITY   (United States)

^b Osco Drugs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BACLOFEN; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLARITHROMYCIN; CLONIDINE; DARIFENACIN; DESMOPRESSIN; DICYCLOVERINE; DIURETIC AGENT; DULOXETINE; ESTROGEN; FLAVOXATE; HYOSCYAMINE; IMIPRAMINE; KETOCONAZOLE; LEVSINEX; NARCOTIC AGENT; OXYBUTYNIN; PAROXETINE; PROPANTHELINE BROMIDE; SOLIFENACIN; TAMSULOSIN; TERAZOSIN; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG;

AGING; BEHAVIOR MODIFICATION; BLADDER CATHETERIZATION; BLADDER DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; CONSTIPATION; CONTINUING EDUCATION; DELIRIUM; DIABETES MELLITUS; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; ELECTROSTIMULATION THERAPY; ESTROGEN DEFICIENCY; EXERCISE; HALLUCINATION; HEART FAILURE; HUMAN; LIFESTYLE; MYDRIASIS; NEUROLOGIC DISEASE; OBESITY; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PATIENT COUNSELING; PATIENT MONITORING; PELVIS FLOOR; PROSTATE HYPERTROPHY; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SLEEP DISORDER; SPINAL CORD INJURY; STRESS INCONTINENCE; TACHYCARDIA; URGE INCONTINENCE; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

EID: 33747883500     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. Adams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: Report for the standardization of Subcommittee of the International Continence Society. Neurourol Urodyn 2002;21:167-178.
2. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002;60(Suppl 5a):7-12.
3. Agency for Health Care Policy and Research (AHCPR). Urinary Incontinence in Adults Guideline Update Panel. Clinical Practice Guidelines: Managing acute and chronic urinary incontinence. Am Fam Physician 1996;54:1661-1671.
4. Milsom L, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-766.
5. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-336.
6. Chutka DS, Takalhashi PY. Urinary incontinence in the elderly. Drugs 1998;56(4):587-595.
7. Rosenthal AJ, McMurtry CT. Urinary incontinence in the elderly. Postgrad Med 1995;97(5):109-121.
8. Salvatore S, Soligo M, Proietti F, et al. Overactive bladder syndrome: Considerations in pharmacotherapy and new perspectives. Eur J Obstet Gynecol Reprod Biol 2005;120(2):129-133.
9. Fourcroy JL. Urogynecology Update: Incontinence. Hosp Practice 1998;33(5):63-81.
10. Andersson KE. New pharmacological targets for the treatment of the overactive bladder: An update. Urology 2004;63(3 Suppl 1):32-41.
11. American Medical Directors Association (AMDA) Clinical Practice Guideline: Urinary Incontinence, 2005. Available at: www.amda.com/info/cpg/ incontinence.htm.
12. Ouslander JG, Bruskewski R. Disorders of micturition in the aging patient. Adv Intern Med 1989;34:165-190.
13. Gosing JA. The structure of the female lower urinary tract and pelvic floor. Urol Clin North Am 1985;12:207.
14. Thompson JF. Geriatric urological disorders. In: Koda Kimble MA, Young LL, eds. Applied Therapeutics: The Clinical Use of Drugs, 8th ed. Vancouver, WA: Applied Therapeutics, Inc.; 2005;101-1-101-33.
15. Abrams P. Describing bladder storage function: Overactive bladder syndrome and detrusor overactivity. Urology 2003;62:28-37.
16. DeGroat WC. A neurological basis for the overactive bladder. Urology 1997;50(Suppl 6a):36-52.
17. Stewart W, Herzog R, Wein A, et al. The prevalence and impact of overactive bladder in the U.S.: Results from the Noble program. Neurourol Urodyn 2001;20:406-408.
18. Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: Current concepts and future prospects. BJU Int 2005;95(3):335-340.
19. Chapple CR, Wein AJ. The urgecy of the problem and the problem of urgency in the overactive bladder. BJU Int 2005;95(3):274-275.
20. Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence. Obstet Gynecol 2001;98:398-406.
21. Tannenbaum C, DuBeau CE. Urinary incontinence in the nursing home: Practical approach to evaluation and management. Clin Geriatr Med 2004;20:437-452.
22. Prochoda KP Medical director's review of urinary incontinence in long-term care. J Am Med Dir Assoc 2003;3(1 Suppl);S11-S15.
23. Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: Does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000;48:721-725.
24. Wagner TH, Hu TW, Bentkover J, et al. Health-related consequences of overactive bladder. Am J Manag Care 2002;8(19 Suppl):S598-S607.
25. Diokno AC, Brock BM, Brown MB, et al. Prevalence of urinary and other urological symptoms in the non-institutionalized elderly. J Urol 1986;136:1022-1025.
26. Ouslander JG, Kane RL, Abrass IB. Urinary incontinence in elderly nursing home patients. JAMA 1982;248:1194-1198.
27. Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: Results from a U.S. community based survey. Urology 2001;57:1044-1050.
28. Brown JS, Grady D, Ouslander J, et al. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Obstet Gynecol 1999;94:66-70.
29. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6:S574-S579.
30. Ricci JA, Baggish JS, Hunt TL, et al. Coping strategies and health care-seeking behavior in a U.S. national sample of adults with symptoms suggestive of overactive bladder. Clin Ther 2001;23:1245-1259.
31. Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995. Urology 1998;51:335-361.
32. Hu TW, Wagner TH. Economic considerations in overactive bladder. Am J Manag Care 2000;6:S591-S598.
33. Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Aging 1997;26:367-374.
34. Kelleher CJ. Economic and social impact of OAB. Eur Urol Suppl 2002;1:11-16.
35. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003;61:1123-1128.
36. Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: Results from a national community survey. Value Health 2004;7:455-463.
37. Zhou SZ, Jensen G. Insurance claims costs for overactive bladder disorder. Drug Benefit Trends 2001;13:45-58.
38. Abrams P Andersson KE, Brubaker L, et al. Third International Consultation on Incontinence. Recommendations of the International Scientific Committee. Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, vol 2. Plymouth, UK: Health Publication Ltd; 2005:1589-1626.
39. Van Kerrebroeck PEV. Neuromuscular and other electro-stimulatory techniques. Scand J Urol Nephrol Suppl 2002;210:82-86.
40. Resnick NM, Blaivas JG, Ostergard DR. Practical pointers on urinary incontinence. Patient Care 1995;29:103-131.
41. Lemack GE. Overactive bladder: Optimizing quality of care. Am J Manag Care 2001;7(2 Suppl):S46-S61.
42. Burgio KL, Locker JL, Goode PS, et al. Behavioral vs. drug treatment for urge incontinence in older women: A randomized controlled trial. JAMA 1998;280(23):2034-2035.
43. Wyman JE, Fantl JA Bladder training in ambulatory care management of urinary incontinence. Urol Nurs 1991;11(3):11-17.
44. Wyman JF, Fantl JA, McClish DK, Bump RC. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. Am J Obstet Gynecol 1998;179(4):999-1007.
45. Hassouna MM, Siegel SW, Nyeholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: A multicenter study on efficacy and safety. J Urol 2000;163:1849-1854.
46. Chartier-Kastler EJ, Rudd Busch JL, Perrigot M, et al. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 2000;164:1476-1480.
47. Aboseif S, Tammadon K, Chalfin S, et al. Sacral neuromodulation as an effective treatment for refractory pelvic floor dysfunction. Urology 2002;60:52-56.
48. Subak LL, Quesenberry CP, Posner SF, et al. The effect of behavioral therapy on urinary incontinence: A randomized controlled trial. Obstet Gynecol 2002;100:72-78.
49. Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: A randomized controlled trial. JAMA 2002;288:2293-2299.
50. Mattiasson A, Blaakaer J, Hoye K, Wein AJ. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. Br J Urol Int 2003;91:54-60.
51. Ouslander JG. Management of overactive bladder. N Engl J Med 2004;350:786-799.
52. Wein AJ. Pharmacologic options for the overactive bladder. Urology 1998;51:43-47.
53. Lepor H, Williford WO, Barry MJ, et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome and factors predicting response. J Urol 1998;160:1358-1367.
54. Dmochowski RR, Appell RA. Advancement in pharmacologic management of overactive bladder. Urology 2000;56(Suppl 6A):41-49.
55. Yoshimura N, Chanceler MB. Current and future pharmacological treatment for overactive bladder. J Urol 2002;168:1897-1913.
56. Johnson TM II, Miller M, Pillion DJ, Ouslander JG. Arginine vasopressin and nocturnal polyuria in older adults with frequent nighttime voiding. J Urol 2003;170:480-484.
57. Martin SW, Radley SC, Chess-Williams R, et al. Relaxant effects of potassium-channel openers on normal and hyper-reflexic detrusor muscle. Br J Urol 1997;80:405-413.
58. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: Current state of the art. Eur Urol 2003;44:165-174.
59. Andersson K-E, Appell R, Cardozo L, et al. Third International Consultation on Incontinence. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, vol 2. Plymouth, UK: Health Publication Ltd., 2005;809-855.
60. Chappie C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: A systematic review and meta-analysis. Eur Urol 2005;48:5-26.
61. Yamaguchi O, Shishido K, Tamura K, et al. Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J Urol 1996;156:1208-1213.
62. Yasuhiko I. Discussion: Functional role of M1, M2 and M3 muscarinic receptors in overactive bladder. Urology 2000;55(5A):47-49.
63. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279-290.
64. Blazer DG II, Federspiel CF, Ray WA, Schaffner W. The risk of anticholinergic toxicity in the elderly: A study of prescribing practices in two populations. J Gerontol 1983;38:31.
65. Brown JH, Palmer T. Muscarinic receptor agonist and antagonists. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill; 1996:141-160.
66. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999;15:15-28. Available at: http://intapp. medscape.com/px/ medlineapp/getdoc?pmi=10459729&cid= med.
67. Goode PS, Burgio KL. Pharmacological treatment of lower urinary tract dysfunction in geriatric patients. Am J Med Sci 1997;314;14(4):262-267.
68. Rondorf-Klyn LM, Colling J, Simonson W. Medication use by community-dwelling elderly with urinary incontinence. Urol Nurs 1998;18(3):201-206.
69. Wei J, Walton EA, Milici A, et al. M1-M5 muscarinic receptor distribution in rat CNS by RT-PCR and HPLC. J Neurochem 1994;63(3):815-821.
70. Power AE, McIntyre CK, Litmanovich A, et al. Cholinergic modulation of memory in the basolateral amygdala involves activation of both M1 and M2 receptors. Behav Pharmacol 2003;14(3):207-213.
71. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41(6):636-644.
72. Tune LE. Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 2000;5(2):149-153.
73. Flicker C, Ferris SH, Serby M. Hypersensitivity to scopolamine in the elderly. Psychopharmacology 1992;107(2-3):437-441.
74. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993;3(4):335-348.
75. Edwards KR, O'Connor JT. Risk of delirium with concurrent use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc 2002;50:1165-1166.
76. Dutcher JA, Miller SW Overactive bladder: Definition, etiology, prevalence and cost. Consult Pharm 2003;18(Suppl B):4-12.
77. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53.
78. Hedges S, Choppin A, Bonhaus D, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro. Br J Pharmacol 1997;120:1409-1418.
79. Newgreen DT, Anderson DW, Carter AJ. Darifenacin: A novel bladder-selective agent for the treatment of urge incontinence. Neurourol Urodyn 1995;14:95-99.
80. Yarker Y, Goa KL, Fitton A Oxybutynin: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-262.
81. Anderson KE, Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology 2002;605(Suppl 1):13-21.
82. Igawa Y, Yamazaki Y, Takeda H, et al. Functional and molecular biological evidence for a possible beta-adrenoceptor in the human detrusor muscle. Br J Pharmacol 1999;126:819-825.
83. Fischer CP, Diokno A, Lapides J. The anticholinergic effects of dicyclomine HCl in uninhibited neurogenic bladder dysfunction. J Urol 1978;120:328-329.
84. Briggs RS, Castleden CM, Asher MJ. The effect of flavoxate on uninhibited detrusor contractions and urinary incontinence in the elderly. J Urol 1980;123:665-666.
85. Chapple CR. Muscarinic receptors antagonists in the treatment of overactive bladder. Urology 2000;55(Suppl 5A):33-46.
86. Holmes DM, Montz FJ, Stanton SL. Oxybutynin versus propantheline in the management of detrusor instability: A patient regulated variable dose trial. Br J Obstet Gynaecol 1989;96:607-612.
87. Thuroff J, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on the treatment of frequency, urgency and incontinence related to detrusor hyperactivity. Oxybutynin versus propantheline versus placebo. J Urol 1991;145:813-817.
88. Andersson KE. The overactive bladder: Pharmacologic basis of drug treatment. Urology 1997;50(Suppl 6a):74-84.
89. Herbison P, Hay-Smith J, Blis G, et al. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: Systemic review. BMJ 2003;326:8414.
90. Enablex (darifenacin). East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2004.
91. VESIcare (solifenacin) tablets. Yamanouchi Pharma America, Inc., and GlaxoSmithKline; 2004.
92. Sanctura (trospium chloride) tablets. Lexington, MA; Indevus Pharmaceuticals, Inc.; 2004.
93. Moisey CU, Stephenson TP, Brendler CB. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Br J Urol 1980;52:472-475.
94. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999;161:1809-1812.
95. Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology 1999;54:420-423.
96. Guay D. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003;42(14):1243-1285.
97. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial. Mayo Clin Proc 2003;78:687-695.
98. Nelson CP Gupta P Napier CM, et al. Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. J Pharmacol Exp Ther 2004;310(3):1255-1265.
99. Nilvebrant L: On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors. Acta Pharmacol Toxicol 1986;59(Suppl 1):1-45.
100. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin in the human detrusor and parotid gland. J Urol 1997;157:1093-1097.
101. Anderson GF, Fredericks CM. Characterization of the oxybutynin antagonism of drug-induced spasms in detrusor. Pharmacology 1977;15:31-39.
102. Tapp AJ, Cardozo LD, Versi E, Cooper D. The treatment of detrusor instability in postmenopausal women with oxybutynin chloride: A double-blind placebo controlled study. Br J Obstet Gynaecol 1990;97:521-526.
103. Riva D, Casolati E. Oxybutynin chloride in the treatment of idiopathic bladder instability: Results from double-blind treatment. Clin Exp Obstet Gynecol 1984;11:37-42.
104. Zorzitto ML, Holliday PJ, Jewett MA, et al. Oxybutynin chloride for geriatric urinary dysfunction: A double-blind placebo-controlled study. Age Aging 1989;18:195-200.
105. Szonyi J, Collas DM, Ding YY, et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: A randomized controlled trial. Age Ageing 1995;24(4):287-291.
106. Barkin J, Corcos J, Radomski S, et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 2004;26:1026-1036.
107. Baigrie RJ, Kelleher JP, Fawcett DP, Pengelly AW. Oxybutynin: Is it safe? Br J Urol 1988;62:319-322.
108. Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-145.
109. Andersson KE, Chapple CR. Oxybutynin and the overactive bladder. World J Urol 2001;19:319-323.
110. Igawa Y. Discussion: Functional role of M1, M2, and M3 muscarinic receptors in overactive bladder. Urology 2000;55(Suppl 5a):47-49.
111. Lai H, Boone T, Appell R. Selecting a medical therapy for overactive bladder. Rev Urol 2002;4(Suppl 4):S28-S37.
112. Caldwell J, Marsh M. Metabolism of drugs by the gastrointestinal tracts. In: George C, Shand D, eds. Clinical Pharmacology and Therapeutics 1: Presystemic Drug Elimination. London: Butterworth Scientific; 1982:29-42.
113. Hebjorn S, Andersen JT, Walter S, Mouritzen DA. Detrusor hyperreflexia: A survey on its etiology and treatment. Scand J Urol Nephrol 1976;10:103-109.
114. Diokno A, Sand P, Labasky R, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: A one-year study. Int Urol Nephrol 2002;34:43-49.
115. Bang LM, Easthope SE, Perry CM. Transdermal oxybutynin for overactive bladder. Drugs Aging 2003;20:857-864.
116. Saltzstein L. Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin. Urol Nurs 2005;25(4):260-262.
117. Dmochowski RR, Sand PK, Zinner NR, et al., for the Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62:237-242.
118. Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterodine: A new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997;327:195-207.
119. Nilvebrant L, Glas G, Jonsson A, et al. The in vitro pharmacological profile of tolterodine: A new drug for the treatment of urinary incontinence. Neurourol Urodyn 1994;13:433-435.
120. Abrams P, Freeman R, Anderstrom C, et al. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-810.
121. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997;50(Suppl 6A):90-96.
122. Millard R, Turtle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999;161:1551-1555.
123. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: A safe and effective treatment for older patients with overactive bladder (Abstract). J Am Geriatr Soc 2001;49:700-705.
124. Rovner ES, Wein AJ. Modern pharmacotherapy of urge urinary incontinence in the USA: Tolterodine and oxybutynin. BJU Intl 2000;86(Suppl 2):44-54.
125. Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J 1999;10:283-289.
126. Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother 2000;11:13-27.
127. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT Study. Mayo Clin Proc 2001;76:358-363.
128. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine Study Group. Tolterodine once daily: Superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-421.
129. Brynne N, Dalén P, Alván G, Bertilsson L, Gabrielsson J. Influence of CYP 2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther 1998;63:529-539.
130. Rovner ES, Wein AJ. Update on overactive bladder: Pharmacologic approaches on the horizon. Curr Urol Rep 2003;4:385-390.
131. Chui M, Williamson T, Arciniega J, et al. Patient persistency with medications for overactive bladder. Value Health 2004;7:366.
132. Hashim H, Abrams P. Drug treatment of overactive bladder: Efficacy, cost and quality-of-life considerations. Drugs 2004;64:1643-1656.
133. Chapple C, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93(3):303-310.
134. Pak RW, Petrou SP, Staskin DR. Trospium chloride: A quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003;4:436-440.
135. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45:420-429.
136. Eglen RM, Watson N. Selective muscarinic receptor agonists and antagonists. Pharmacol Toxicol 1996;78:59-68.
137. Walls RM, Napier CM. Muscarinic antagonists in development for disorders of smooth muscle function. Life Sci 1999;64:395-401.
138. Madersbacher H, Stȯhrer, Richter R, et al. Trospium chloride versus oxybutynin: A randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 1995;75:452-456.
139. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003;20:392-399.
140. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: A multicenter phase III trial. J Urol 2004;171:2311-2315.
141. Cardozo L, Chapple CR, Toozs-Hobson M, et al. Efficacy of trospium chloride in patients with detrusor instability: A placebo-controlled, randomized, double blind multicentre clinical trial. BJU Int 2000;85:659-664.
142. Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994;47:337-343.
143. Breuel HP, Mürtz G, Bondy S, et al. Safety and tolerance of trospium chloride in the high dose range. Arzneimittelforschung 1993;43(4):461-464.
144. Beckmann-Knopp S, Rietbrock S, Weyenmeyer R, et al. Inhibitory effects of trospium chloride on cytochrome P540 enzymes in human liver microsomes. Pharmacol Toxicol 1999;85(6):299-304.
145. Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004;64(21):2433-2446.
146. Fusgen I, Iiauri D. Trospium chloride: An effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther 2000;38:223-234.
147. Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonist by the novel antimuscarin[ic] agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002;366:97-103.
148. Brunton S, Kuritzky L. Recent developments in the management of overactive bladder: Focus on the efficacy and tolerability of once-daily solifenacin succinate 5 mg. Curr Med Res Opin 2005;21:71-80.
149. Chappie C, Wyndaele JJ, Gronen S, for the Solifenacin Study Group. Solifenacin provided statistically significant and clinically relevant reductions in urgency, a defining symptom of overactive bladder. Neurourol Urodyn 2004;23:316.
150. Cardozo L, Castro-Diaz D, Gittelman M, et al. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct (electronic publication, April 20, 2006).
151. Haab F, Cardozo L, Chapple C, Ridder AM, for the Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005;47:376-384.
152. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo-controlled trial of the once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-1924.
153. Kelleher C, Cardozo L, Chapple C, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Intl 2005;95:81-85.
154. Cardozo L, Chapple CR, Swift S, et al, for the Solifenacin Study Group. Solifenacin was effective and well tolerated in patients of all ages. Third International Consultation on Incontinence, June 26-29, 2004, Monte Carlo.
155. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol 2005;48:464-470.
156. Chapple CR. Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Invest Drugs 2004;13(11):1493-1500.
157. Foote JE. Darifenacin, a highly M3 selective muscarinic receptor antagonist, is effective and well tolerated by elderly patients with overactive bladder. J Am Geriatr Soc 2004;52:S126.
158. Zinner N, Tuttle JB, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist, compared with oxybutynin in the treatment of patients with overactive bladder. International Continence Society Meeting, Paris, France, 2004.
159. Khullar V. Darifenacin, an M3 selective receptor antagonist, reduces the frequency of nocturnal awakening, and important symptom of overactive bladder (Abstract 491). J Urol 2004;171 (4 Suppl):131.
160. Robinson D, Khullar V, Cardozo L. Pharmacological management of detrusor instability. Int Urogynecol J 2001;12:271-278.
161. Braverman AS, Ruggieri MR, Pontari MA. The M2 muscarinic receptor subtype medicates cholinergic bladder contractions in patients with neurogenic bladder dysfunction. J Urol 2001;165:36.
162. Braverman AS, Tallarida R, Ruggieri MR. Interaction between muscarinic receptors subtype signal transduction pathways mediating bladder contraction. Am J Physiol Regul Integr Comp Physiol 2002;283:1-6.
163. Ouslander J, Maloney C, Graselat Rogers L, et al. Implementation of a nursing home urinary incontinence management program with and without tolterodine. J Am Med Director Assoc 2001;2:207-214.
164. Burgio KL, Locker J, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatric Soc 2000;48:370-374.
165. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997;104:988-993.
166. Hofer K, Oelke M, Machtens S, et al. Trospium chloride: An effective drug in the treatment of overactive bladder and detrusor hyper-reflexia. World J Urol 2001;19:336-343.